Evidence map›Paper›PMID 41851070›Full record

ArticleSignal transduction and targeted therapy2026

Spi-1 proto-oncogene regulates mRNA hypertranscription and malignant progression in head and neck cancer.

Zheran Liu, Zijian Qin, Huilin Li, Lili Zhu, Ling He, Na Chen, Dan Zhu, Qinghong Liu, Lei Dai, Xingchen Peng

Abstract read
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zheran Liu *Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Zijian Qin *Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Huilin Li *Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Lili ZhuDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Ling HeDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Na ChenState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China.
Dan ZhuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China.
Qinghong LiuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China.
Lei DaiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China. dailei2016@scu.edu.cn.
Xingchen PengDepartment of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. pxx2014@163.com.ORCID http://orcid.org/0000-0001-7042-718X

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82473434
6 · The paper itself

Abstract

Head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent and lethal cancers worldwide. Despite multimodal therapeutic advances, long-term survival remains poor, underscoring the need to identify novel molecular drivers of disease aggressiveness. Hypertranscription is a genome-wide increase in total RNA output that has emerged as a hallmark of oncogenic transformation. However, the role of mRNA-specific hypertranscription in HNSCC and its underlying molecular drivers remain undefined. In the present study, we investigated the association between mRNA hypertranscription and malignant phenotypes in HNSCC. Single-cell transcriptomics data revealed that elevated mRNA hypertranscription was significantly associated with the activation of oncogenic pathways and poor clinical outcomes. Through transcription factor activity analysis, we identified the transcription factor Spi-1 Proto-Oncogene (SPI1) as a potential regulator of mRNA hypertranscription in HNSCC malignant cells. Loss- and gain-of-function experiments in HNSCC cell lines and xenograft models established that SPI1 drives cell proliferation, invasion, migration, and tumor growth in vitro and in vivo. Mechanistically, inducible SPI1 overexpression elevated nascent RNA synthesis as measured by EU incorporation, and integrative ChIP-seq/RNA-seq profiling identified direct genomic targets of SPI1 enriched in oncogenic transcriptional programs. Collectively, our findings show that SPI1-driven mRNA hypertranscription is important in HNSCC progression and provide novel insights into the transcriptional dysregulation underlying aggressive malignancies.

Indexed as

Gene Expression Regulation, NeoplasticHead and Neck NeoplasmsRNA, MessengerSquamous Cell Carcinoma of Head and NeckTrans-ActivatorsAnimalsCell Line, TumorCell ProliferationDisease ProgressionHumansMiceProto-Oncogene MasMAS1 protein, humanProto-Oncogene MasRNA, MessengerTrans-Activators

Identifiers

PMID41851070
PMCPMC13000193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.